A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness
Sabeena Ahmed, Mohammad Mahbubul Karim, Allen G Ross, Mohammad Sharif Hossain, John D Clemens, Mariya Kibtiya Sumiya, Ching Swe Phru, Mustafizur Rahman, Khalequ Zaman, Jyoti Somani, Rubina Yasmin, Mohammad Abul Hasnat, Ahmedul Kabir, Asma Binte Aziz, Wasif Ali Khan, Sabeena Ahmed, Mohammad Mahbubul Karim, Allen G Ross, Mohammad Sharif Hossain, John D Clemens, Mariya Kibtiya Sumiya, Ching Swe Phru, Mustafizur Rahman, Khalequ Zaman, Jyoti Somani, Rubina Yasmin, Mohammad Abul Hasnat, Ahmedul Kabir, Asma Binte Aziz, Wasif Ali Khan
Abstract
Ivermectin, a US Food and Drug Administration-approved anti-parasitic agent, was found to inhibit severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) replication in vitro. A randomized, double-blind, placebo-controlled trial was conducted to determine the rapidity of viral clearance and safety of ivermectin among adult SARS-CoV-2 patients. The trial included 72 hospitalized patients in Dhaka, Bangladesh, who were assigned to one of three groups: oral ivermectin alone (12 mg once daily for 5 days), oral ivermectin in combination with doxycycline (12 mg ivermectin single dose and 200 mg doxycycline on day 1, followed by 100 mg every 12 h for the next 4 days), and a placebo control group. Clinical symptoms of fever, cough, and sore throat were comparable among the three groups. Virological clearance was earlier in the 5-day ivermectin treatment arm when compared to the placebo group (9.7 days vs 12.7 days; p = 0.02), but this was not the case for the ivermectin + doxycycline arm (11.5 days; p = 0.27). There were no severe adverse drug events recorded in the study. A 5-day course of ivermectin was found to be safe and effective in treating adult patients with mild COVID-19. Larger trials will be needed to confirm these preliminary findings.
Keywords: Bangladesh; COVID-19; Doxycycline; Ivermectin; SARS-CoV-2.
Conflict of interest statement
The authors declare that there are no known competing financial interests or personal relationships that could have appeared to influence the work described in this paper.
Copyright © 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.
Figures
References
- Alam M.T., Murshed R., Bhiuyan E., Saber S., Alam R., Robin R. A Case Series of 100 COVID-19 Positive Patients Treated with Combination of Ivermectin and Doxycycline. J Bangladesh Coll Physic Surg. 2020;38:10–15. doi: 10.3329/jbcps.v38i0.47512.
- Caly L., Druce J.D., Catton M.G., Jans D.A., Wagstaff K.M. 2020. "The FDA-approved Drug Ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res, from (Caly et al. 2020), Apr 3.
- Centers for Disease Control and Prevention . 2020. Interim Clinical Guidance for Management of Patients with Confirmed 2019 Novel Coronavirus (2019-nCoV) Infection, Updated March 7, 2020. [Available from: [accessed 17.11.2020]
- Chiu S.H., Lu A.Y. Metabolism and tissue residues. In: Campbell W.C., editor. Ivermectin and Abamectin. Springer-Verlag; New York, NY: 1989. pp. 131–143.
- Johns Hopkins University of Medicine COVID-19 . 2020. COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University. (accessed 17.11.2020)
- Lespine A., Alvinerie M., Sutra J.F., Pors I., Chartier C. Influence of the route of administration on efficacy and tissue distribution of ivermectin in goat. Vet Parasitol. 2005;128:251–260.
- Rajter J.C., Sherman M.S., Fatteh N., Vogel F., Sacks J., Rajter J.J. ICON (Ivermectin in COvid Nineteen) study: use of ivermectin is associated with lower mortality in hospitalised patients with COVID-19. medRxiv. 2020;2020 06.06.20124461.
- Wu C., Liu Y., Yang Y. Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. Acta Pharm Sin B. 2020 doi: 10.1016/j.apsb.2020.02.008.
Source: PubMed